α-GPCが認知機能とスポーツパフォーマンスに及ぼす効果
成人における認知機能およびスポーツパフォーマンスに対するアルファ-グリセロホスホコリン（α-GPC）の効果に関する無作為化二重盲検プラセボ対照研究
The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period.
The main questions this study aims to answer are:
Does taking α-GPC every day improve cognitive performance on tests such as the Stroop Test, Go/No-go Test, Sustained Attention to Response Task (SART), and Digit-Symbol Substitution Test (DSST)? Does α-GPC enhance upper and lower body sports performance? Does α-GPC positively affect perceived mood, energy, and motivation? Is α-GPC safe and well tolerated compared to a placebo? Researchers will compare α-GPC (350 mg per day) to a placebo (an inactive substance that looks the same) in a randomized, double-blind study. Neither the participants nor the researchers will know who receives α-GPC or the placebo.
Participants will:
Be randomly assigned to take either α-GPC or placebo capsules once daily for 6 weeks Attend 3 study visits over an 8-week period at Atlantia Clinical Trials in Cork, Ireland Complete cognitive and physical performance tests both acutely (shortly after a single dose) and after 6 weeks of daily use Have their vital signs, body weight, and any adverse events monitored throughout the study Record their diet and well-being during the study period This study will include 80 healthy adults aged 25-55 years who regularly engage in physical activity. The results will help determine whether α-GPC has benefits for brain function and physical performance, and whether it is safe for long-term use.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
County Cork
-
Cork、County Cork、アイルランド、P56 W9X2
- Atlantia Clinical Trials
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Be able to give written informed consent.
- Be in good health as determined by the investigator.
- Age between 25 and 55 years (inclusive).
- Body Mass Index of 18.5-32.0 kg/m2 (inclusive).
- Body weight of at least 54 kilograms.
- Muscle strengthening activities 2-3 time per week or participation in recreational or local level moderate intensity activity for at least 2 years.
- Normotensive (resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg).
- Willing to duplicate their previous 24-hr diet, refrain from alcohol and caffeine for 24-hr prior to each visit, refrain from exercise 48-hr prior to each visit.
- Refrain from consuming beef liver, chicken liver, eggs, fish, wheat germ and soybeans, butter beans 24-hrs prior to Visit 2 and Visit 3.
Exclusion Criteria:
- Highly trained or competitive athletes.
- Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
- Female participants who are currently breastfeeding.
- Female participants who are planning to become pregnant during the study period.
- Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product.
- Participants with history of drug and/or alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); alcohol/substance abuse disorder).
- Caffeine intake of three or more cups of coffee or equivalent (>400 mg) per day.
- Current smokers or users of any nicotine products in the past 4-weeks.
- Has food allergies or other issues with foods that would preclude intake of the Study Products.
- Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer.
- Diagnosed, uncontrolled psychiatric disorder.
- Hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
- Prior gastrointestinal bypass surgery (excluding appendectomy).
- Gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism.
- Chronic inflammatory condition or disease.
- History of severe or chronic musculoskeletal pain or injury.
- History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD.
- Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.
- Use CNS stimulants or anxiety or ADHD medication.
- Use corticosteroids (oral, subcutaneous, intramuscular, or transdermal only).
- Use testosterone replacement therapy (ingestion, injection, or transdermal).
- Current or recent use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.
- Use creatine, BCAA, HMB, betaine, beta-alanine, in the past 2 weeks.
- Use choline supplements (e.g. choline bitartrate, phosphatidylcholine, citicholine) in the past 4 weeks.
- Use omega-3, ginkgo biloba, ginseng, L-theanine, Lion's Mane, ashwagandha in the past 4 weeks.
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
- Participants may be participating in other clinical studies.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター：プラセボ
|
Participants will oral one capsule containing 350 mg of microcrystalline cellulose (MCC) daily before breakfast for 6 weeks. |
|
実験的：食品添加物: 315 mg α-GPC
|
Participants will oral one capsule containing 350 mg of GeniusPure® (containing 315 mg of pure α-GPC) daily before breakfast for 6 weeks. |
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive Performance - Stroop Test-Stroop total score
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the stroop total score change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive Performance - Stroop Test - Stroop accuracy (%)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the stroop accuracy (%) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive Performance - Stroop Test - Stroop time per score (s)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the stroop time per score (s) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Number of Correct Symbols (N)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the Number of Correct Symbols (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Total Correct Score
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the Total Correct Score change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Accuracy (%)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the Accuracy (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Time per Correct Response (s/item)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test the Time per Correct Response (s/item) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive performance - Go/No-go Test - Correct responses (N)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Go/No-Go - Correct responses (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test - Errors of omissions (%)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Go/No-Go - Errors of omissions (%) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test - Errors of commission (%)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Go/No-Go - Errors of commission (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test - Correct rejections (N)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Go/No-Go - Correct rejections (N) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test - Mean response times (mins)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Go/No-Go - Mean response times (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test - Reaction time (mins)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Reaction time (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive performance - Go/No-go Test- Reaction time variability (RTV)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the Reaction time variability (RTV) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Cognitive Performance - Sustained Attention to Response Task (SART) - Total Commission Errors (N)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test total commission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive Performance - Sustained Attention to Response Task (SART) - Omission Errors (N)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test omission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time (Mean RT)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test reaction time (Mean RT) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time Variability (RTV)
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
Test reaction time variability (RTV) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo on. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
|
|
Upper Body Power - Average power (W)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
The average power (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Upper Body Power - Peak power production (W)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
The peak power production (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Upper Body Power - Peak Velocity (m/s)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
The peak velocity (m/s) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Upper Body Power - Peak force production (N)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
The peak force production (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Lower Body Power - Average power (W)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the average power (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo). |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Lower Body Power - Peak power production (W)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the peak power production (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo). |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Lower Body Power - Peak Velocity (m/s)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the peak Velocity (m/s) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo). |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Lower Body Power - Peak force production (N)
時間枠：Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Test the peak force production (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo). |
Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Perceived mood assessment
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Perceived mood assessed using the Visual Analog Scale (VAS), a 0-100 scale where 0 indicates 'worst mood imaginable' and 100 indicates 'best mood imaginable.' Higher scores represent better perceived mood. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Perceived motivation assessment
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Perceived motivation assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no motivation' and 100 indicates 'maximum motivation.' Higher scores represent better perceived motivation. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Perceived energy assessment
時間枠：Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Perceived energy assessed using the VAS, with a range of 0-100 where 0 indicates 'no energy' and 100 indicates 'maximum energy.' Higher scores represent better perceived energy. |
Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Heart Rate Measurement
時間枠：Assessed at 0(before ingestion of assigned test product ), 60 and 190 min(after ingestion product) during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Accurately measure heart rate using a dedicated heart rate monitor. |
Assessed at 0(before ingestion of assigned test product ), 60 and 190 min(after ingestion product) during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Blood Pressure Measurement (Systolic and Diastolic)
時間枠：Assessed at 0(before ingestion of assigned test product ), 60 and 190 min(after ingestion product) during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Blood pressure measured using an automated sphygmomanometer. Both systolic and diastolic pressures will be assessed. |
Assessed at 0(before ingestion of assigned test product ), 60 and 190 min(after ingestion product) during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Dietary Energy Intake
時間枠：During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
24-Hour Dietary Intake using 24-hour recall approach.Dietary calorie intake(kcal) were evaluated. |
During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Dietary macronutrient intake
時間枠：During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
24-Hour Dietary Intake using 24-hour recall approach. Dietary macronutrient intake(g) were evaluated. |
During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
|
Temperature
時間枠：During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
Forehead temperature was measured using an electronic thermometer. |
During baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
|
協力者と研究者
協力者
協力者
出版物と役立つリンク
一般刊行物
- Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5.
- Yamashita S, Kawada N, Wang W, Susaki K, Takeda Y, Kimura M, Iwama Y, Miura Y, Sugano M, Matsuoka R. Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study. Lipids Health Dis. 2023 Jun 20;22(1):75. doi: 10.1186/s12944-023-01844-w.
- Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024 Dec 9;16(23):4240. doi: 10.3390/nu16234240.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NNB2025HCS-AFCRO-199
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。